Drug Approval | June 12, 2022
Strides receives USFDA approval for Ibuprofen OTC oral suspension
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Strides was granted a Competitive Generic Therapy (CGT) designation for its ANDA.
Marinus has broadened inclusion criteria in the RAISE trial to allow for enrollment of patients previously treated with IV anesthesia.
During the research term, Olema will contribute funding to Aurigene to facilitate ongoing discovery efforts.
Healthcare is timely and personal – and its delivery should be too
Bayer now present in four of the largest biotechnology hubs in the United States
TP-3654 is currently being evaluated in a Phase 1/2, multicenter, dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics in patients with intermediate or high-risk primary or secondary myelofibrosis.
Based on a post hoc analysis, fewer required respiratory interventions
he approved product has an estimated market size of US$ 83 million for the twelve months ending April 2022, according to IQVIA.
TLANDO was approved by the U.S. Food and Drug Administration (FDA) on March 28, 2022.
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
Subscribe To Our Newsletter & Stay Updated
